[Pulmonary Hypertension Associated with Lung Diseases]

Pulmonary hypertension associated with chronic lung diseases (PH-CLD) is one of the most common but frequently underdiagnosed forms of pulmonary hypertension (PH). Its presence has been consistently associated with worse prognosis and reduced quality of life for affected patients. Recent epidemiological data highlight the heterogeneity of this patient population, demonstrating that both the underlying lung disease and the severity of PH are critical determinants of prognosis and therapeutic decisions. The 7th World Symposium on Pulmonary Hypertension (WSPH) emphasized the importance of systematic diagnostic approaches and detailed phenotyping of PH-CLD. While some studies have shown potential benefits of PH-targeted therapies, others - particularly in COPD - have reported adverse outcomes. This position statement by the PH-DACH working group summarizes the key recommendations of the 11th Task Force of the 7th WSPH, critically assesses the current evidence, and comments specifically on deviations from the original text. The aim is to contribute to the development of practical diagnostic and therapeutic algorithms for patients with PH-CLD.